Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase II drugs for Muscle Invasive Bladder Cancer (MIBC) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lesabelimab LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lesabelimab overview

Monoclonal antibody is under development for the treatment of advanced malignant tumors including invasive bladder cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma and penile squamous cell carcinoma, endometrial cancer, cervical cancer, ovarian cancer, colorectal cancer, advanced non-clear cell renal cancer and advanced penile cancer and unspecified indication. It acts by targeting PD L1. The drug candidate is administered as injection.

Dragonboat Biopharmaceutical (Shanghai) overview

Dragonboat Biopharmaceutical (Shanghai) (Dragonboat Biopharmaceutical), a subsidiary of Guilin Sanjin Pharmaceutical Co Ltd, is a biopharmaceutical company that researches and develops biologics for cancers and autoimmune diseases. The company pipeline product includes BC003, BC001, BC005, BC006, BC007, BC008, BC010, BC011 and BCT2101. Dragonboat Biopharmaceutical drug candidate targets include solid tumors, tenosynovial giant cell tumors, asthma, gastric cancer and pancreatic cancer among others. It also utilizes an In-house systemic platform. The company operates a drug research and development center that covers early discovery, preclinical research, IND, clinical research, biologics license application and manufacturing. Dragonboat Biopharmaceutical is headquartered in Shanghai, China.

For a complete picture of Lesabelimab’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.